Revvity, Inc.
NYSE:RVTYMedical - Diagnostics & Research
-$3.40 today
- Market cap
- $17.02B
- Beta
- 1.11
- P/E (TTM)
- 45.4
- EPS (TTM)
- $2.15
- Dividend yield
- 0.29%
Volume 1.09M
Average 1.27M
RVTY Total Equity
Shareholders' claim on the company's assets after all liabilities: total assets minus total liabilities.
Revvity, Inc.NYSE: RVTY
Total Equity · Q2 FY2026 · quarter ended Jul 2026
Total equity falls 4.3% from a year ago
Total equity stood at $7.23B at the end of Q2 FY2026, down 4.3% from a year earlier and up 0.6% from the prior quarter. Over 3 fiscal years it compounded at -0.6% a year.
Context
- Total equity amounted to 60.0% of total assets at the end of Q2 FY2026, down 1.1 pp from a year earlier.
- Total equity increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether total equity keeps falling in the next quarterly balance sheet after a -4.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Equity history
USD · from the balance sheet
- Latest · FY2025
- 7.25B USD
- Year-over-year change
- -5.4%
- 4-year CAGR
- +0.4%
| Period | Period end | Total Equity | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-28 | 7.25B | -5.4% |
| FY2024 | 2024-12-29 | 7.67B | -2.6% |
| FY2023 | 2023-12-31 | 7.87B | +6.6% |
| FY2022 | 2022-12-31 | 7.38B | +3.4% |
| FY2021 | 2021-12-31 | 7.14B | — |
Total Equity vs competitors
How RVTY compares with its peers on the latest reported figures
- RVTY's Jul 2026 total equity of $7.23B is the 5th highest of the 11 companies compared; the peer median is $5.27B.
- Its year-over-year change of -4.3% is the 10th highest of 11, against a peer median of +8.7%.
- Total equity amounts to 60.0% of total assets for RVTY, versus a peer median of 54.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $54.9B | +7.3% | +6.6% | 48.1% | |
| Sep 2026 | $53.63B | +5.0% | +1.6% | 57.5% | |
| Jul 2026 | $15.2B | +603.5% | +71.9% | 61.4% | |
| Jul 2026 | $7.36B | +15.6% | +8.3% | 52.7% | |
| Jul 2026 | $7.23B | -4.3% | -0.6% | 60.0% | |
| Jun 2026 | $7.17B | +0.6% | -8.1% | 70.0% | |
| Jun 2026 | $3.36B | -4.2% | +2.9% | 57.0% | |
| Jun 2026 | $2.85B | -16.3% | +2.0% | 37.8% | |
| Sep 2026 | $2.17B | +10.2% | +2.3% | 82.1% | |
| Mar 2026 | $186.25M | +16.5% | -22.1% | 43.5% | |
| Jun 2026 | $12.82M | +105.0% | — | 0.3% | |
| Peer median (excluding RVTY) | $5.27B | +8.7% | +2.3% | 54.9% | |
Competitors are the stored peer set for RVTY. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 603.32M | 454.36M | 913.16M | 1.16B | 919.87M |
| Short-term Investments | 0 | 0 | 689.92M | 0 | 0 |
| Net Receivables | 707.94M | 612.78M | 632.81M | 632.4M | 744.67M |
| Inventory | 425.89M | 405.46M | 428.06M | 367.59M | 379.5M |
| Other Current Assets | 703.63M | 1.82B | 337.14M | 186.23M | 195.71M |
| Total Current Assets | 2.44B | 3.29B | 3B | 2.35B | 2.24B |
| Property, Plant & Equipment (Net) | 649.57M | 671.3M | 664.74M | 649.93M | 644.69M |
| Goodwill | 6.63B | 6.48B | 6.53B | 6.46B | 6.61B |
| Intangible Assets | 3.82B | 3.38B | 3.02B | 2.64B | 2.35B |
| Long-term Investments | 110.94M | 144.62M | 0 | 124.94M | 1.16M |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1.35B | 166.44M | 342.97M | 163.45M | 322.32M |
| Total Non-current Assets | 12.56B | 10.84B | 10.56B | 10.04B | 9.93B |
| Total Assets | 15B | 14.13B | 13.56B | 12.39B | 12.17B |
| Account Payables | 324.81M | 272.83M | 204.12M | 167.46M | 185.46M |
| Short-term Debt | 4.24M | 470.93M | 721.87M | 242K | 588.83M |
| Tax Payables | 90.96M | 45.63M | 88.16M | 0 | 0 |
| Deferred Revenue | 138.05M | 135.53M | 135.56M | 140.21M | 0 |
| Other Current Liabilities | 257.79M | 324.85M | 43.28M | 44.18M | 556.95M |
| Total Current Liabilities | 1.21B | 1.54B | 1.45B | 653.1M | 1.33B |
| Long-term Debt | 4.98B | 3.92B | 3.18B | 3.15B | 2.78B |
| Deferred Tax Liabilities | 1.43B | 1.11B | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 91.7M | 0 | 930.95M | 770.52M | 659.35M |
| Total Non-current Liabilities | 6.65B | 5.2B | 4.24B | 4.07B | 3.59B |
| Total Liabilities | 7.86B | 6.75B | 5.69B | 4.73B | 4.92B |
| Common Stock | 126.24M | 126.3M | 123.43M | 120.65M | 112.28M |
| Retained Earnings | 4.42B | 4.95B | 5.61B | 5.85B | 6.05B |
| Accumulated OCI | (162.69M) | (447.5M) | (276.69M) | (396.11M) | (222.14M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 7.14B | 7.38B | 7.87B | 7.67B | 7.25B |
| Total Debt | 5.16B | 4.6B | 4.07B | 3.33B | 3.52B |
| Net Debt | 4.56B | 4.14B | 3.15B | 2.16B | 2.6B |
Revvity, Inc.
NYSE:RVTY
Intrinsic Alpha fair value
Locked
Current Price
$152.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.